Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.92 |
| ▸ | SRC | P12931 | 5/20 | 0.92 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.92 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.92 |
| ▸ | EGFR | P00533 | 2/20 | 0.92 |
| ▸ | LCK | P06239 | 2/20 | 0.92 |
| ▸ | FYN | P06241 | 2/20 | 0.92 |
| ▸ | CSF1R | P07333 | 2/20 | 0.92 |
| ▸ | YES1 | P07947 | 2/20 | 0.92 |
| ▸ | LYN | P07948 | 2/20 | 0.92 |
| ▸ | RET | P07949 | 2/20 | 0.92 |
| ▸ | HCK | P08631 | 2/20 | 0.92 |
| ▸ | KIT | P10721 | 2/20 | 0.92 |
| ▸ | BCR | P11274 | 2/20 | 0.92 |
| ▸ | BRAF | P15056 | 2/20 | 0.92 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.92 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.92 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.92 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.92 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasatinib Anhydrous SCHEMBL29381185 | 0.96 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.96 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL28350326 | 0.96 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL29377489 | 0.95 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL28828268 | 0.95 | ABL1 (0.98) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL29482416 | 0.95 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL16618598 | 0.95 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL28432270 | 0.95 | ABL1 (0.98) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.95 | ABL1 (0.98) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL1705152 | 0.95 | ABL1 (0.98) | ABL1SRCPKMYT1EPHB6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-11-06 | — | — | US | disclosed |
| US-12338440-B2 | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | IOMX THERAPEUTICS AG (DE) | 2025-06-24 | — | — | US | disclosed |
| US-20210040486-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-02-11 | — | — | US | disclosed |
| US-20210040486-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-02-11 | — | — | US | disclosed |
| EP-3391907-A1 | INTRACELLULAR KINASE SIK3 ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2018-10-24 | — | — | EP | disclosed |
| EP-2960341-B1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3263717-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2018-01-03 | — | — | EP | disclosed |
| US-20170315128-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| EP-2435581-B1 | METHODS OF USE OF A NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) | MOLECULAR HEALTH GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2960341-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2015-12-30 | — | — | EP | disclosed |
| EP-2492355-B1 | Tissue protective erythropoietin receptor (nepor) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-20140296318-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8357501-B2 | Tissue protective erythropoietin receptor (NEPOR) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| EP-2109690-B9 | EPH-B4 SPECIFIC SIRNA FOR REDUCING EPO-INDUCED TUMOR CELL GROWTH DURING ANEMIA TREATMENT IN CANCER PATIENTS, TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE. | MOLECULAR HEALTH GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245087-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2012-09-27 | — | — | US | disclosed |
| EP-2492355-A1 | Tissue protective erythropoietin receptor (nepor) and methods of use | Life Biosystems GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2109690-B1 | EPH-B4 SPECIFIC SIRNA FOR REDUCING EPO-INDUCED TUMOR CELL GROWTH DURING ANEMIA TREATMENT IN CANCER PATIENTS, TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE. | MOLECULAR HEALTH GMBH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20090306186-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040486-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | SIK3, SIK1, SIK2 | ABL1 1088/4885SRC 859/4885PKMYT1 2522/4885 |
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | SIK3, SIK1, SIK2 | ABL1 1088/4885SRC 859/4885PKMYT1 2522/4885 |
| US-12338440-B2 | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | SIK3, SIK1, SIK2 | ABL1 1088/4885SRC 859/4885PKMYT1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.